Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 2/20 | 0.36 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.34 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.34 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | CCL2 | P13500 | 1/20 | 0.34 |
| ▸ | CCL5 | P13501 | 1/20 | 0.34 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7890382 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL12304926 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL19276555 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL17484873 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL15942923 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL17484892 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL17484890 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL17484891 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL19276443 | 1.00 | M6PR (0.41) | M6PRLGALS8F10SUCNR1G6PD | |
| SCHEMBL12458629 | 0.93 | F10 (0.43) | M6PRLGALS8F10G6PDSERPINC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802156-B2 | Pharmaceutical forms for the release of active compounds | LABORATORIOS FARMACÉUTICOS ROVI, S.A. (ES) | 2014-08-12 | — | — | US | disclosed |
| US-20120022020-A1 | PHARMACEUTICAL FORMS FOR THE RELEASE OF ACTIVE COMPOUNDS | LABORATORIOS FARMACEUTICOS ROVI S.A. (ES) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022020-A1 | PHARMACEUTICAL FORMS FOR THE RELEASE OF ACTIVE COMPOUNDS | ALG1, HPSE, GAA | M6PR 107/4885LGALS8 520/4885F10 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.